Identification of the KIF18A alpha-4 helix as a therapeutic target for chromosomally unstable tumor cells

Katherine Schutt1, Katelyn A Queen1, Kira Fisher1

  • 1Department of Molecular Physiology and Biophysics, University of Vermont, Burlington, VT.

Insights

The mitotic kinesin KIF18A is crucial for cancer cell proliferation. Targeting its alpha-4 helix with small molecules effectively inhibits chromosome instability (CIN) tumor growth.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • KIF18A is a mitotic kinesin essential for chromosome instability (CIN) cancer cell proliferation.
  • Targeting KIF18A is a promising strategy for aggressive tumor types.
  • Identifying specific KIF18A regions for inhibition is key for drug development.

Approach:

  • Investigated the role of serine 284 (S284) mutation in the KIF18A alpha-4 helix.
  • Observed KIF18A relocalization and loss of function in S284 mutants.
  • Compared effects of genetic mutation with KIF18A inhibitory compounds.

Key Points:

  • Mutating S284 in KIF18A's alpha-4 helix disrupts its microtubule localization and function.
  • KIF18A S284 mutants impair proliferation in CIN tumor cells.
  • Small molecules targeting the KIF18A alpha-4 helix mimic genetic perturbation effects.

Conclusions:

  • The KIF18A alpha-4 helix is a viable target for therapeutic inhibition.
  • Small molecule inhibitors targeting KIF18A selectively reduce CIN tumor cell proliferation.
  • Inhibition of KIF18A leads to mitosis defects similar to genetic mutations.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K